hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06344507, orgStudyIdInfo id: TAILOR-EUS, briefTitle: Iconographic Registry of Pancreatobiliary Endoscopy Procedures, acronym: TAILOR-EUS, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-03-28, primaryCompletionDateStruct date: 2027-12-31, completionDateStruct date: 2027-12-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: IRCCS San Raffaele, class: OTHER, descriptionModule briefSummary: The aim of the TAILOR-EUS study (Iconographic Registry of Bilio-Pancreatic Endoscopic Ultrasound Procedures) is to establish a clinical registry comprising images and videos generated during endoscopic procedures conducted for the investigation of pancreatic diseases (PD). The study will compile historical, pathological, and imaging data from approximately 12,000 patients (2,000 retrospectively and 10,000 prospectively) who underwent endoscopic ultrasound procedures for inflammatory pancreatic conditions (e.g., acute, recurrent, chronic pancreatitis), autoimmune bilio-pancreatic diseases (e.g., autoimmune pancreatitis), neoplastic bilio-pancreatic conditions, and screenings for individuals at high risk of developing such diseases at the Bilio-Pancreatic Endoscopy and Endoscopic Ultrasound Unit of the IRCCS San Raffaele Hospital between 2000 and 2027.Participants have undergone or will undergo the standard diagnostic pathway appropriate for their conditions as part of routine clinical practice. All instrumental examinations and endoscopic ultrasound procedures are integral to the standard diagnostic and therapeutic approach for pancreatic diseases., conditionsModule conditions: Pancreas Neoplasm, conditions: Cancer of Pancreas, conditions: Pancreatitis, conditions: Neuroendocrine Tumors, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: OTHER, enrollmentInfo count: 12000, type: ESTIMATED, outcomesModule primaryOutcomes measure: Registry for images and videos, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS San Raffaele Hospital, status: RECRUITING, city: Milan, zip: 20132, country: Italy, contacts name: Matteo Tacelli, MD, role: CONTACT, email: tacelli.matteo@hsr.it, geoPoint lat: 45.46427, lon: 9.18951, hasResults: False
protocolSection identificationModule nctId: NCT06344481, orgStudyIdInfo id: CL-00003, briefTitle: The Hyalex First-in-Human Study, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-07, primaryCompletionDateStruct date: 2026-09, completionDateStruct date: 2026-09, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-12, sponsorCollaboratorsModule leadSponsor name: Hyalex Orthopaedics, Inc., class: INDUSTRY, descriptionModule briefSummary: The Hyalex First-in-Human Study is a prospective, multicenter, open-label, single-arm, 2-phase, first-in-human study to evaluate the safety and technical performance of the HYALEX Knee Cartilage System for replacement of loss of articular cartilage and bone of the knee femoral condyles in symptomatic patients who require surgical treatment., conditionsModule conditions: Cartilage Injury, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Surgical (Hyalex Cartilage Knee Implant), outcomesModule primaryOutcomes measure: Freedom from implant rejection and infection., primaryOutcomes measure: Change in the Knee Injury & Osteoarthritis Outcome Score (KOOS) from baseline at 12 months., eligibilityModule sex: ALL, minimumAge: 21 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: SPORTO, status: RECRUITING, city: Łódź, zip: 09-038, country: Poland, contacts name: Klaudia Marchewa, role: CONTACT, email: marchewa.klaudia@gmail.com, contacts name: Marcin Domzalski, M.D., role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 51.75, lon: 19.46667, hasResults: False
protocolSection identificationModule nctId: NCT06344416, orgStudyIdInfo id: RXG-001-2024-CLP (Rex-002), briefTitle: Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-30, primaryCompletionDateStruct date: 2025-03-30, completionDateStruct date: 2026-01-30, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Dosentrx Ltd., class: INDUSTRY, descriptionModule briefSummary: Primary Objective:• To assess the persistence of ReX technology platform use, measured by the percentage (%) of participants who used ReX: 1) throughout the study period and 2) before the treatment discontinuation.Secondary Objective:• To evaluate the impact of the ReX technology platform on ribo treatment duration and ribo dose taking adherence as compared to control group., conditionsModule conditions: Any Solid Oral Medication, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SEQUENTIAL, interventionModelDescription: Study groups, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, maskingDescription: A minimum of 50 and a maximum of 200 patient charts are expected to be reviewed for the control study group., whoMasked: PARTICIPANT, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Use of ReX to dispense and monitor solid oral medication therapy., outcomesModule primaryOutcomes measure: Outcome MeasureReX Platform Study Group, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: OHC, city: Cincinnati, state: Ohio, zip: 45242, country: United States, geoPoint lat: 39.12713, lon: -84.51435, hasResults: False
protocolSection identificationModule nctId: NCT06344403, orgStudyIdInfo id: KY2024-045-02, briefTitle: Clinical Efficacy and Safety of Tender Point Infiltration (TPI) for Acute and Subacute Zoster Associated Pain, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2025-03-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Beijing Tiantan Hospital, class: OTHER, descriptionModule briefSummary: Herpes zoster (HZ) is a skin infection disease which cause severe zoster-associated pain (ZAP) along sensory nerve in the corresponding segment. Evidence for the efficacy of existing local therapies for acute/subacute ZAP is limited. The hypothesis is that patients with acute/subacute ZAP treated with TPIs with local anesthetic and steroids under the basis of standard treatment will show better clinical outcomes compared with subjects treated with standard antiviral medicine treatment only., conditionsModule conditions: Herpes Zoster, conditions: Local Infiltration, conditions: Acute Pain, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 136, type: ESTIMATED, armsInterventionsModule interventions name: analgesic, interventions name: Tender point infiltration, outcomesModule primaryOutcomes measure: The presence of postherpetic neuralgia using VAS score, secondaryOutcomes measure: visual analogue scale score at each time point, secondaryOutcomes measure: Proportion of patients receiving repeated TPIs and block points, secondaryOutcomes measure: Consumption of oral drugs at each time point, secondaryOutcomes measure: The presence of PHN 3 and month 6 post treatment, secondaryOutcomes measure: Patient satisfaction scores on the 5-point Likert scale, secondaryOutcomes measure: Quality of life on the Scores on the WHOQOL-BREF, secondaryOutcomes measure: Adverse reactions through study completion, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beijing Tiantan Hospital, status: RECRUITING, city: Beijing, state: Beijing, zip: 100070, country: China, contacts name: Luo Fang, M.D, role: CONTACT, phone: +86 13611326978, email: 13611326978@163.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06344390, orgStudyIdInfo id: 20210327, briefTitle: Effect of Pentoxifylline on Cognitive Impairment After Ischemic Stroke, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-10, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: The First Hospital of Hebei Medical University, class: OTHER, descriptionModule briefSummary: Pentoxifylline can improve cognitive impairment after ischemic stroke, possibly by improving the level of cerebral blood flow, affecting the content of blood oxygen and metabolic substances in the brain, and then playing a protective role in the transmission of nerve electrical signals, and ultimately improving cognitive function. The patients with cognitive impairment and non-dementia PSCIND after ischemic stroke were randomly divided into two groups. In addition to the basic drugs of ischemic stroke, the patients were given pentothemine sustained release tablets and blank control respectively to observe the effects of pentothemine on cognitive function and neuronal electrical signals in the patients with ischemic PSCIND. It is expected to explore the possible internal biological mechanism by using transcranial Doppler, oxygen-dependent functional magnetic resonance imaging and craniocerebral magnetic resonance pop analysis. Finally, statistical correlation analysis was used to elucidate the specific mechanism of pentoxifylline in improving cognitive function of non-dementia patients with cognitive impairment after ischemic stroke., conditionsModule conditions: Cognitive Impairment, designModule studyType: INTERVENTIONAL, phases: PHASE1, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Pentoxifylline, outcomesModule primaryOutcomes measure: Pentoxifylline can improve cognitive impairment after ischemic stroke, eligibilityModule sex: ALL, minimumAge: 40 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: BHan, status: RECRUITING, city: Shijiazhuang, country: China, contacts name: Jiaying Rong, role: CONTACT, phone: 15241876265, email: rjy19982023@163.com, geoPoint lat: 38.04139, lon: 114.47861, hasResults: False
protocolSection identificationModule nctId: NCT06344351, orgStudyIdInfo id: TQB3006-I-01, briefTitle: A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-25, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2026-08, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Chia Tai Tianqing Pharmaceutical Group Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: This study includes two stage: dose escalation and dose extension, with a single dose and a multiple dose study. This is a single-center, open, non-randomized, single arm, study to evaluate the safety, tolerability and pharmacokinetics of TQB3006 tables in patients with advanced malignant cancer., conditionsModule conditions: Advanced Malignant Neoplasm, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 93, type: ESTIMATED, armsInterventionsModule interventions name: TQB3006 tablets, outcomesModule primaryOutcomes measure: Dose limiting toxicity (DLT), primaryOutcomes measure: Maximum tolerated dose (MTD), primaryOutcomes measure: Recommended phase II dose (RP2D), secondaryOutcomes measure: Adverse events (AE), secondaryOutcomes measure: Serious adverse events (SAE), secondaryOutcomes measure: Time to reach maximum plasma concentration (Tmax), secondaryOutcomes measure: Peak concentration (Cmax), secondaryOutcomes measure: Half-life (t1/2), secondaryOutcomes measure: Area under the concentration-time curve (AUC [0-infinity]), secondaryOutcomes measure: Area under the concentration-time curve (AUC [0-t]), secondaryOutcomes measure: Apparent clearance (CL/F), secondaryOutcomes measure: Apparent volume of distribution (Vd/F), secondaryOutcomes measure: Objective response rate (ORR), eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Harbin Medical University Cancer Hospital, status: RECRUITING, city: Harbin, state: Heilongjiang, zip: 150000, country: China, contacts name: Tongsen Zheng, Doctor, role: CONTACT, phone: 15134569619, email: zhengtongsen@126.com, geoPoint lat: 45.75, lon: 126.65, hasResults: False
protocolSection identificationModule nctId: NCT06344338, orgStudyIdInfo id: Z211100002921030, briefTitle: Application of tDCS Stimulation in Controlling Refractory Status Epilepticus, acronym: tDCS, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-31, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Xuanwu Hospital, Beijing, class: OTHER, descriptionModule briefSummary: The purpose of the study is to assess the efficacy and safety of targeting tDCS stimulation for treatment of Refractory status epilepticus, conditionsModule conditions: Refractory Status Epilepticus, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: The patients who meet the eligibility requirements will be randomized in a 1:1 ratio to undergo targeting tDCS stimulation (up to 10 times) or sham stimulation, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, enrollmentInfo count: 32, type: ESTIMATED, armsInterventionsModule interventions name: tDCS stimulation, interventions name: TDCS sham-stimulation, outcomesModule primaryOutcomes measure: Number of participants with status epilepticus termination between tDCS treatment group and tDCS sham--stimulation group as assessed by Salzburg Consensus Criteria for Non-Convulsive Status Epilepticus, secondaryOutcomes measure: Number of participants with treatment-related adverse events between tDCS treatment group and tDCS sham--stimulation group, eligibilityModule sex: ALL, minimumAge: 14 Years, maximumAge: 80 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Xuanwu Hospital, Capital Medical University, status: RECRUITING, city: Beijing, state: Beijing, zip: 100053, country: China, contacts name: Weibi Chen, role: CONTACT, phone: +8615010255903, email: chenweibi@126.com, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06344325, orgStudyIdInfo id: EDPP, briefTitle: ED90 of Fospropofol Disodium in Induction and Maintenance of Anesthesia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2026-03-31, completionDateStruct date: 2026-03-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Tongji Hospital, class: OTHER, descriptionModule briefSummary: Exploring the 90% effective dose (ED90) of fospropofol disodium in induction and maintenance of anesthesia in adults of different ages, providing more clinical evidence for the application of fospropofol disodium in clinical anesthesia, conditionsModule conditions: Elective Surgery, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: NON_RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 330, type: ESTIMATED, armsInterventionsModule interventions name: fospropofol, outcomesModule primaryOutcomes measure: Sedation score, secondaryOutcomes measure: Postoperative adverse reactions, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tongji hospital, city: Wuhan, state: Hubei, zip: 430030, country: China, contacts name: Aijun Xu, Dr., role: CONTACT, phone: +8618627784217, email: ajxu@tjh.tjmu.edu.cn, geoPoint lat: 30.58333, lon: 114.26667, hasResults: False
protocolSection identificationModule nctId: NCT06344312, orgStudyIdInfo id: M2023551, briefTitle: Effectiveness of Yangxue Qingnao Granules in Preventing Post Thrombolytic Hemorrhage Transformation in Patients With Acute Cerebral Infarction, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-01-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-06-01, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Peking University Third Hospital, class: OTHER, descriptionModule briefSummary: Evaluate the effectiveness of Yangxue Qingnao Granules in preventing post thrombolytic hemorrhage transformation in patients with acute cerebral infarction, and explore its possible mechanism, conditionsModule conditions: Stroke, Acute Ischemic, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Yangxue Qingnao Granules, outcomesModule primaryOutcomes measure: The proportion of subjects with mRS score ≤ 1 on the 90th day of treatment, eligibilityModule sex: ALL, minimumAge: 50 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University Third Hospital, city: Beijing, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06344299, orgStudyIdInfo id: HuaDong Hosiptal of FUDAN, briefTitle: Predictors for Low Rates of Surgical Resection in Elderly Patients With Resectable Pancreatic Ductal Adenocarcinoma, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-01-01, primaryCompletionDateStruct date: 2023-06-30, completionDateStruct date: 2023-09-30, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: More and more older adults are diagnosed with pancreatic ductal adenocarcinoma (PDAC), but the rate of surgical resection in patients with resectable tumour is still low. Clinical workers need to take more attention to oncologic care in this group. It's significant to explore potential predictors for impacting elderly patients chose to abandon surgical resection., conditionsModule conditions: Pancreatic Ductal Adenocarcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 5302, type: ACTUAL, armsInterventionsModule interventions name: potential predictors, outcomesModule primaryOutcomes measure: ORs of potential predictors, secondaryOutcomes measure: Overall survival (OS), eligibilityModule sex: ALL, minimumAge: 75 Years, maximumAge: 100 Years, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Huadong Hospital affiliated to Fudan University, city: Shanghai, zip: 200040, country: China, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06344286, orgStudyIdInfo id: IstanbulTRH-DArman-002, briefTitle: The Effects of Minimal Enteral Nutrition on Mesenteric Blood Flow and Oxygenation in Neonates With HIE, statusModule overallStatus: COMPLETED, startDateStruct date: 2020-09-01, primaryCompletionDateStruct date: 2022-08-31, completionDateStruct date: 2022-10-31, studyFirstPostDateStruct date: 2024-04-03, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Istanbul Training and Research Hospital, class: OTHER_GOV, descriptionModule briefSummary: The goal of this clinical trial is to evaluate the effects of minimal enteral nutrition (MEN) on mesenteric blood flow and oxygenation with Doppler USG and Near Infrared Spectroscopy (NIRS) during therapeutic hypo¬thermia (TH) in babies with hypoxic ischemic encephalopathy. The main question it aims to answer is:1- How do the mesenteric blood flow and oxygenation get affected with MEN during TH? Participants will be either fed with MEN during TH or given placebo., conditionsModule conditions: Hypoxic-Ischemic Encephalopathy, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: An enteral intake of breast milk with a volume of 10-20 mL/kg/day was defined as minimal enteral feeding. Minimal enteral feeding was initiated at postnatal 24 hours with breast milk via an orogastric tube. A total daily intake of 120 ml/kg/day was defined as full enteral feeding.The babies were randomized into two groups based on whether they received MEN during TH. While the babies fed with MEN during TH constituted the study group, the control group was composed of the babies who were given the same amount of distilled water according to the same protocol. Two groups were compared in terms of demographic characteristics, clinical outcomes, NIRS and Doppler measurements., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: TRIPLE, maskingDescription: The feeding materials were prepared inside an opaque syringe and serially numbered by Total Parenteral Nutrition Department in our institution. The investigators who made all measurements, examinations and collected data, and the nurses of the babies were blinded. All of the infants in the study group were fed with breast milk during the trial., whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, enrollmentInfo count: 60, type: ACTUAL, armsInterventionsModule interventions name: Minimal enteral nutrition, interventions name: Distilled water, outcomesModule primaryOutcomes measure: Cerebral and mesenteric blood flow velocities and oxygenation, primaryOutcomes measure: Cerebral and mesenteric rSO2 values, secondaryOutcomes measure: Development of NEC, secondaryOutcomes measure: Feeding intolerance, secondaryOutcomes measure: Time to full enteral feeding, eligibilityModule sex: ALL, minimumAge: 0 Days, maximumAge: 1 Day, stdAges: CHILD, contactsLocationsModule locations facility: IstanbulTRH, city: Istanbul, country: Turkey, geoPoint lat: 41.01384, lon: 28.94966, hasResults: False